The VECAT study: Vitamin E, cataract & age related macular degeneration

A. P. Thomas, S. K.M. Garrett, L. D. Robman, C. A. McCarty, M. Sinclair, J. J. McNeil, H. R. Taylor

Research output: Contribution to journalArticleResearchpeer-review

Abstract

PURPOSE. To describe the methodological features of a prospective interventional study, examining the effects of anti-oxidant supplementation on progression of lens opacities and ARM. METHODS: VECAT is a four year, prospective double masked, randomised, placebo controlled clinical trial. 1200 participants aged 55-80 yrs have been recruited from the general population in Melbourne, and randomised to Vitamin E (500 i.u daily) or placebo. Study procedures include; 1) assessment of primary end points by serial clinical grading of lens opacities and macular pathology, NIDEK EAS-1000 digital image analysis of lens opacities, and NIDEK 3D/X stereo macular photography, 2) assessment of secondary end points by serial LogMAR visual acuity and VF-14 visual function questionnaire, 3) collection of historical data relating to known risk factors for cataract and 4) collection of data to assess adverse effects attributable to study medication. RESULTS: VECAT has recruited the baseline population of 1200 participants from the general community. Recruitment statistics and baseline clinical characteristics are presented elsewhere. CONCLUSIONS: Any intervention to reduce cataract or ARM would have enormous benefits. Evidence suggesting a role for anti-oxidants comes largely from animal studies and human observational studies. This needs to be tested by prospective large scale studies such as VECAT.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
Publication statusPublished - 15 Feb 1996

Cite this